Minors vaccinated in Muntinlupa number 17,700 – Manila Bulletin

The city government of Muntinlupa vaccinated nearly 18,000 minors between the ages of 12 and 17 in almost a month.

As of November 21, according to the Muntinlupa COVID-19 vaccination program (MunCoVac), a total of 17,773 minors have received their first dose of the COVID-19 vaccine.

Vaccination of a minor in Muntinlupa (Muntinlupa PIO)

The total is equivalent to 32 percent of Muntinlupa’s estimated total population of 55,391 minors belonging to the 12-17 age group. In addition, 547 minors received the second dose, making them fully vaccinated.

In total, the city government has already administered 18,320 vaccine injections to minors since it began immunizing the pediatric population on October 25.

As of November 21, 33,662 minors have registered with MunCoVac for vaccination, or 61% of the total population for this age group.

Of the total, 2,449 minors (7.3%) have comorbidities or are classified as pediatric category A3, while 31,213 (92.7%) are classified as “healthy children”.

Minors with comorbidities are only vaccinated at the Ospital ng Muntinlupa, managed by the city. For those who do not have one, they are vaccinated at SM Center Muntinlupa, Ayala Malls South Park, New Cupang Health Center, and Sucat Covered Field.

According to the guidelines of the Ministry of Health, the comorbidities eligible for pediatric A3 vaccination are medical complexity, genetic diseases, neurological diseases, metabolic / endocrine diseases, cardiovascular diseases, obesity, HIV infection , tuberculosis, chronic respiratory diseases, kidney disorders, hepatobiliary diseases. and an immunocompromised state due to disease or treatment.

The Philippine Food and Drug Administration (FDA) has approved the Pfizer-BioNTech and Moderna vaccines for use in people 12 years of age and older.

As of November 21, Muntinlupa had 70 active cases of COVID-19 out of 27,585 confirmed cases, 26,937 recoveries and 578 deaths.


SUBSCRIBE TO THE DAILY NEWSLETTER

CLICK HERE TO JOIN


Source link

Comments are closed.